Johnson & Johnson, a global healthcare leader, has announced its definitive agreement to acquire Ambrx Biopharma, Inc., as communicated by Biljana Naumovic, Worldwide Vice President, Oncology, on LinkedIn on January 29, 2024. The acquisition is subject to customary closing conditions, including antitrust clearances and approval by Ambrx stockholders. Concerns have been raised regarding potential risks and uncertainties that could affect the transaction's completion and the anticipated benefits. These include regulatory approvals, the reaction of the businesses and employees during the transaction period, and the integration of Ambrx's operations into Johnson & Johnson's portfolio. The definitive proxy statement was filed by Ambrx with the SEC on January 29, 2024, and will be mailed to stockholders on February 2, 2024. Investors and stockholders are advised to read the proxy statement and other relevant documents filed with the SEC for more information about the proposed transaction.

Johnson & Johnson, a global healthcare leader, has announced its definitive agreement to acquire Ambrx Biopharma, Inc., as communicated by Biljana Naumovic, Worldwide Vice President, Oncology, on LinkedIn on January 29, 2024. The acquisition is subject to customary closing conditions, including antitrust clearances and approval by Ambrx stockholders. Concerns have been raised regarding potential risks and uncertainties that could affect the transaction's completion and the anticipated benefits. These include regulatory approvals, the reaction of the businesses and employees during the transaction period, and the integration of Ambrx's operations into Johnson & Johnson's portfolio. The definitive proxy statement was filed by Ambrx with the SEC on January 29, 2024, and will be mailed to stockholders on February 2, 2024. Investors and stockholders are advised to read the proxy statement and other relevant documents filed with the SEC for more information about the proposed transaction.